menu
    • menu
    [{"orgOrder":0,"company":"Amryt Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"IRELAND","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Lomitapide","moa":"Microsomal triglyceride transfer protein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Amryt Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Amryt Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Amryt Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Amryt Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"IRELAND","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Lomitapide","moa":"Microsomal triglyceride transfer protein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Amryt Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Amryt Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Amryt Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Amryt Pharma","sponsor":"Medison Pharma","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"IRELAND","productType":"Miscellaneous","year":"2021","type":"Agreement","leadProduct":"Lomitapide","moa":"Microsomal triglyceride transfer protein","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Amryt Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Amryt Pharma \/ Medison Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Amryt Pharma \/ Medison Pharma"},{"orgOrder":0,"company":"Swixx BioPharma","sponsor":"Amryt Pharma","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Miscellaneous","year":"2020","type":"Agreement","leadProduct":"Lomitapide","moa":"Microsomal triglyceride transfer protein","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Swixx BioPharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Swixx BioPharma \/ Amryt Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Swixx BioPharma \/ Amryt Pharma"},{"orgOrder":0,"company":"AEGERION","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Lomitapide","moa":"Microsomal triglyceride transfer protein","graph1":"Genetic Disease","graph2":"Phase III","graph3":"AEGERION","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AEGERION \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AEGERION \/ Undisclosed"},{"orgOrder":0,"company":"AEGERION","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Lomitapide","moa":"Microsomal triglyceride transfer protein","graph1":"Genetic Disease","graph2":"Phase III","graph3":"AEGERION","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AEGERION \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"AEGERION \/ Undisclosed"},{"orgOrder":0,"company":"AEGERION","sponsor":"University of Pennsylvania | Doris Duke Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Lomitapide","moa":"Microsomal triglyceride transfer protein","graph1":"Genetic Disease","graph2":"Phase III","graph3":"AEGERION","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AEGERION \/ University of Pennsylvania | Doris Duke Foundation","highestDevelopmentStatusID":"10","companyTruncated":"AEGERION \/ University of Pennsylvania | Doris Duke Foundation"},{"orgOrder":0,"company":"AEGERION","sponsor":"Richmond Pharmacology","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Lomitapide","moa":"Microsomal triglyceride transfer protein","graph1":"Undisclosed","graph2":"Phase I","graph3":"AEGERION","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AEGERION \/ Richmond Pharmacology","highestDevelopmentStatusID":"6","companyTruncated":"AEGERION \/ Richmond Pharmacology"},{"orgOrder":0,"company":"AEGERION","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Lomitapide","moa":"Microsomal triglyceride transfer protein","graph1":"Undisclosed","graph2":"Phase I","graph3":"AEGERION","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AEGERION \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"AEGERION \/ Undisclosed"},{"orgOrder":0,"company":"AEGERION","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Lomitapide","moa":"Microsomal triglyceride transfer protein","graph1":"Undisclosed","graph2":"Phase I","graph3":"AEGERION","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AEGERION \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"AEGERION \/ Undisclosed"},{"orgOrder":0,"company":"AEGERION","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Lomitapide","moa":"Microsomal triglyceride transfer protein","graph1":"Undisclosed","graph2":"Phase I","graph3":"AEGERION","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AEGERION \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"AEGERION \/ Undisclosed"},{"orgOrder":0,"company":"AEGERION","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Lomitapide","moa":"Microsomal triglyceride transfer protein","graph1":"Undisclosed","graph2":"Phase I","graph3":"AEGERION","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AEGERION \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"AEGERION \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals for Lomitapide

    Menu

    Lomitapide

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Amryt Pharma

                            Ireland arrow
                            AAPS
                            Not Confirmed

                            Amryt Pharma

                            Ireland arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lomitapide

                            Therapeutic Area : Genetic Disease

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Amryt Announces Positive Top Line Results from Phase 3 Pediatric Trial of Lomitapide in HoFH

                            Details : Lojuxta (lomitapide) is approved as an adjunct to a low-fat diet and other lipid-lowering medicinal products for adults with the rare cholesterol disorder, Homozygous Familial Hypercholesterolemia ("HoFH").

                            Product Name : Lojuxta

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 05, 2023

                            Lead Product(s) : Lomitapide

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Amryt Pharma

                            Ireland arrow
                            AAPS
                            Not Confirmed

                            Amryt Pharma

                            Ireland arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lomitapide

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Approved FDF

                            Sponsor : Medison Pharma

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Amryt and Medison Pharma Sign Multi-Regional Distribution Agreements in Canada and Israel

                            Details : Under the terms of the agreement, Medison Pharma will distribute Juxtapid® (lomitapide) in Canada and Lojuxta® (lomitapide) and Myalept® (metreleptin) in Israel.

                            Product Name : Juxtapid

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            February 04, 2021

                            Lead Product(s) : Lomitapide

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : Medison Pharma

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Amryt Pharma

                            Ireland arrow
                            AAPS
                            Not Confirmed

                            Amryt Pharma

                            Ireland arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lomitapide

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacy and Safety of Lomitapide in Paediatric Patients With Homozygous Familial Hypercholesterolaemia (HoFH)

                            Details : Lomitapide is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Homozygous Familial Hypercholesterolemia.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 23, 2020

                            Lead Product(s) : Lomitapide

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Swixx BioPharma

                            Switzerland arrow
                            AAPS
                            Not Confirmed

                            Swixx BioPharma

                            Switzerland arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lomitapide

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Approved FDF

                            Sponsor : Amryt Pharma

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Amryt and Swixx Sign Distribution Deal for Lojuxta

                            Details : Under the agreement, Swixx will distribute Lojuxta® from October 2020 in Albania, Bosnia and Herzegovina, Bulgaria, Croatia, Estonia, Kosovo, Latvia, Lithuania, Montenegro, North Macedonia, Poland, Romania, Serbia and Slovakia.

                            Product Name : Lojuxta

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            October 19, 2020

                            Lead Product(s) : Lomitapide

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : Amryt Pharma

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            AEGERION

                            U.S.A arrow
                            AAPS
                            Not Confirmed

                            AEGERION

                            U.S.A arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lomitapide

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Evaluate the Efficacy and Safety of Lomitapide in Pediatric Patients With Homozygous Familial Hypercholesterol...

                            Details : Lomitapide is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Homozygous Familial Hypercholesterolemia.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            May 09, 2016

                            Lead Product(s) : Lomitapide

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            AEGERION

                            U.S.A arrow
                            AAPS
                            Not Confirmed

                            AEGERION

                            U.S.A arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lomitapide

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacy and Safety of Lomitapide in Japanese Patients With HoFH on Concurrent Lipid-Lowering Therapy

                            Details : Lomitapide is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Homozygous Familial Hypercholesterolemia.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 24, 2014

                            Lead Product(s) : Lomitapide

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            AEGERION

                            U.S.A arrow
                            AAPS
                            Not Confirmed

                            AEGERION

                            U.S.A arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lomitapide

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Evaluate the Effect of Atorvastatin on the Pharmacokinetics of Lomitapide in Healthy Subjects.

                            Details : Lomitapide is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 06, 2014

                            Lead Product(s) : Lomitapide

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            AEGERION

                            U.S.A arrow
                            AAPS
                            Not Confirmed

                            AEGERION

                            U.S.A arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lomitapide

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Evaluate the Effect of Ethinyl Estradiol/Norgestimate on the Pharmacokinetics of Lomitapide in Healthy Female ...

                            Details : Lomitapide is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 06, 2014

                            Lead Product(s) : Lomitapide

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            AEGERION

                            U.S.A arrow
                            AAPS
                            Not Confirmed

                            AEGERION

                            U.S.A arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lomitapide

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Comparative Bioavailability Study of Lomitapide 20 mg Intact vs Sprinkled

                            Details : Lomitapide is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 24, 2014

                            Lead Product(s) : Lomitapide

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            AEGERION

                            U.S.A arrow
                            AAPS
                            Not Confirmed

                            AEGERION

                            U.S.A arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lomitapide

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study to Determine the Intra-subject Variability of Pharmacokinetics of Lomitapide in Healthy Subjects

                            Details : Lomitapide is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 05, 2013

                            Lead Product(s) : Lomitapide

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth